Imprinting of BALB/c mice with low Leishmania infantum parasite dose markedly protects spleen against high-dose challenge

Vaccine

Volumn 24, Issue 5, 2006, Pages 589-596

  Ferrua, Bernard ^a   Luci, Carmelo ^b   Le Fichoux, Yves ^a,c   Paul, Audrey ^a   Marty, Pierre ^a,c  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Leishmania infantum; Protection; Th1 Th2

Indexed keywords

LEISHMANIA VACCINE; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MEGADOSE; FEMALE; IMMUNIZATION; LEISHMANIA INFANTUM; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TH2 CELL;

ANIMALS; ANTIBODIES, PROTOZOAN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; PARASITE EGG COUNT; SPLEEN;

EID: 29544441747     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.08.057     Document Type: Article

References (39)

1. J. Alvar Leishmaniasis and AIDS co-infection: the Spanish example Parasitol Today 10 1994 160 163
2. P. del Giudice, M. Mary-Krause, C. Pradier, S. Grabar, P. Dellamonica, P. Marty French Hospital Database on HIV Clinical Epidemiologic Group Impact of highly active antiretroviral therapy on the incidence of visceral Leishmaniasis in a French cohort of patients infected with human immunodeficiency virus J Infect Dis 186 2002 1366 1370
3. Y. Le Fichoux, D. Rousseau, B. Ferrua, S. Ruette, A. Lelievre, and D. Grousson Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice Antimicrob Agents Chemother 42 1998 654 658
4. S. Ahmed, M. Colmenares, L. Soong, K. Goldsmith-Pestana, L. Munstermann, and R. Molina Intradermal infection model for pathogenesis and vaccine studies of murine visceral Leishmaniasis Infect Immun 71 2003 401 410
5. V. Leclercq, M. Lebastard, Y. Belkaid, J. Louis, and G. Milon The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: a tissue-dependent pattern controlled by the Lsh and MHC loci J Immunol 157 1996 4537 4545
6. P.M. Kaye, M. Svensson, M. Ato, A. Maroof, R. Polley, and S. Stager The immunopathology of experimental visceral Leishmaniasis Immunol Rev 201 2004 239 253
7. C.R. Engwerda, M.L. Murphy, S.E. Cotterell, S.C. Smelt, and P.M. Kaye Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani Eur J Immunol 28 1998 669 680
8. M.E. Wilson, M. Sandor, A.M. Blum, B.M. Young, A. Metwali, and D. Elliott Local suppression of IFN-gamma in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi J Immunol 156 1996 2231 2239
9. M.M. Kane, and D.M. Mosser The role of IL-10 in promoting disease progression in Leishmaniasis J Immunol 166 2001 1141 1147
10. M.E. Wilson, B.M. Young, B.L. Davidson, K.A. Mente, and S.E. McGowan The importance of TGF-beta in murine visceral Leishmaniasis J Immunol 161 1998 6148 6155
11. G.D. Miralles, M.Y. Stoeckle, D.F. McDermott, F.D. Finkelman, and H.W. Murray Th1 and Th2 cell-associated cytokines in experimental visceral Leishmaniasis Infect Immun 62 1994 1058 1063
12. J. Mauel Vaccination against Leishmania infections Curr Drug Targets Immune Endocr Metabol Disord 2 2002 201 226
13. E. Handman Leishmaniasis: current status of vaccine development Clin Microbiol Rev 14 2001 229 243
14. M. Ghosh, and S. Bandyopadhyay Present status of anti Leishmanial vaccines Mol Cell Biochem 253 2003 199 205
15. A. Ghosh, W.W. Zhang, and G. Matlashewski Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections Vaccine 20 2001 59 66
16. S. Stager, D.F. Smith, and P.M. Kaye Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral Leishmaniasis J Immunol 165 2000 7064 7071
17. E. Paraguai de Souza, R.R. Bernardo, M. Palatnik, and C.B. Palatnik de Sousa Vaccination of Balb/c mice against experimental visceral Leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani Vaccine 19 2001 3104 3115
18. C.L. Jaffe, N. Rachamim, and R. Sarfstein Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral Leishmaniasis J Immunol 144 1990 699 706
19. K. Fragaki, I. Suffia, B. Ferrua, D. Rousseau, Y. Le Fichoux, and J. Kubar Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters Vaccine 19 2001 1701 1709
20. T. Mazumdar, K. Anam, and N. Ali A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice Vaccine 22 2004 1162 1171
21. P. Tewary, J. Pandya, J. Mehta, B. Sukumaran, and R. Madhubala Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection FEMS Immunol Med Microbiol 42 2004 241 248
22. S. Mukhopadhyay, S. Bhattacharyya, R. Majhi, T. De, K. Naskar, and S. Majumdar Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis Clin Diagn Lab Immunol 7 2000 233 240
23. J.A. Streit, T.J. Recker, F.G. Filho, S.M. Beverley, and M.E. Wilson Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms J Immunol 166 2001 1921 1929
24. W.R. Santos, V.M. de Lima, E.P. de Souza, R.R. Bernardo, M. Palatnik, and C.B. de Sousa Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis Vaccine 21 2002 30 43
25. P.C. Melby, J. Yang, W. Zhao, L.E. Perez, and J. Cheng Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis Infect Immun 69 2001 4719 4725
26. F. Afrin, and N. Ali Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes Infect Immun 65 1997 2371 2377
27. J.N. Menon, and P.A. Bretscher Parasite dose determines the Th1/Th2 nature of the response to Leishmania major independently of infection route and strain of host or parasite Eur J Immunol 28 1998 4020 4028
28. P.A. Bretscher, G. Wei, J.N. Menon, and H. Bielefeldt-Ohmann Establishment of stable, cell-mediated immunity that makes " susceptible" mice resistant to Leishmania major Science 257 1992 539 542
29. D. Rousseau, S. Demartino, F. Anjuere, B. Ferrua, K. Fragaki, and Y. Le Fichoux Sustained parasite burden in the spleen of Leishmania infantum-infected BALB/c mice is accompanied by expression of MCP-1 transcripts and lack of protection against challenge Eur Cytokine Netw 12 2001 340 347
30. R.G. Titus, M. Marchand, T. Boon, and J.A. Louis A limiting dilution assay for quantifying Leishmania major in tissues of infected mice Parasite Immunol 7 1985 545 555
31. B. Ferrua, Y. Le Fichoux, I. Suffia, D. Rousseau, C. Roptin, and J. Kubar Quantitation of Leishmania infantum in tissues of infected BALB/c mouse by sandwich ELISA J Immunoassay Immunochem 22 2001 165 181
32. J.E. Uzonna, G. Wei, D. Yurkowski, and P. Bretscher Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease J Immunol 167 2001 6967 6974
33. P. Scott, D. Artis, J. Uzonna, and C. Zaph The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development Immunol Rev 201 2004 318 338
34. S. Buates, and G. Matlashewski General suppression of macrophage gene expression during Leishmania donovani infection J Immunol 166 2001 3416 3422
35. S. Stager, J. Alexander, K.C. Carter, F. Brombacher, and P.M. Kaye Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal anti Leishmanial activity Infect Immun 71 2003 4804 4807
36. D. McMahon-Pratt, and J. Alexander Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol Rev 201 2004 206 224
37. A.Y. Karulin, M.D. Hesse, H.C. Yip, and P.V. Lehmann Indirect IL-4 pathway in type 1 immunity J Immunol 168 2002 545 553
38. P.M. Kaye, A.J. Curry, and J.M. Blackwell Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis J Immunol 146 1991 2763 2770
39. K. Kemp, M. Kemp, A. Kharazmi, A. Ismail, J.A. Kurtzhals, and L. Hviid Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis Clin Exp Immunol 116 1999 500 504